The huge sales of the new crown vaccine caused Pfizer to raise its full-year sales forecast. On November 2, Pfizer announced its third-quarter financial report.Sales in the third quarter were approximately US$24 billion, which more than doubled over the same period last year, of which vaccine revenue of US$13 billion was the largest contributor.Pfizer raised its sales forecast for the new crown vaccine this year to about 36 billion U.S. dollars, an increase of about 7%.
Pfizer CEO Albert Bourla said on the performance conference call that more than 75% of vaccine sales this year came from international sales, and vaccines have been sold in 152 countries.
At the same time, the United States is preparing to distribute vaccines to 28 million children aged 5 to 11.
Bora said that taking into account the expected delivery of about 2.3 billion vaccines this year, the company has increased its production capacity and is cooperating with other companies overseas for production.
There is still demand for the new crown vaccine on a global scale. Some countries are receiving initial vaccine supply, some countries have started booster vaccination, and there are still some countries that have not yet received any vaccine supply.
The US FDA last week approved the emergency use authorization for the mRNA vaccine jointly developed by Pfizer and the German company BNT for vaccination in children aged 5-11. Previously, only vaccinations for people over 16 years old and emergency vaccinations for children 12 years old and over were approved.
Bora said in an interview that Pfizer plans to produce about 4 billion doses next year and has already received orders for 1.7 billion doses.
Risk warning and exemption clause
Market risk, the investment need to be cautious. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial situation or needs of individual users. Users should consider whether any opinions, opinions or conclusions in this article are in accordance with their specific conditions. Invest accordingly at your own risk.